- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
PET aids neuroblastoma management decisions
Children's hospitals in Cincinnati and Memphis, TN, have established the value of FDG-PET for depicting the extent of neuroblastoma in some patients, particularly for those in the early stages of the disease.
Children's hospitals in Cincinnati and Memphis, TN, have established the value of FDG-PET for depicting the extent of neuroblastoma in some patients, particularly for those in the early stages of the disease.
Lead author Dr. Susan E. Sharp, an assistant professor of clinical radiology at Cincinnati Children's Hospital Medical Center, and colleagues reviewed a total of 113 paired planar and SPECT Iodine-123I-metaiodobenzylguanidine (MIBG) and FDG-PET/CT scans in 60 patients with neuroblastoma. The investigators found that for stage 1 and stage 2 neuroblastoma patients, FDG-PET depicted more primary or residual neuroblastoma. However, they also found MIBG imaging may be needed to exclude higher stage disease that has spread to the bone or bone marrow (J Nucl Med 2009;50[8]:1237-1243).
PET Agent Gets FDA Fast Track Designation for Cardiac AL and ATTR Amyloidosis
January 22nd 2025Previously approved for the detection of neuritic beta amyloid plaque, the PET agent (18F)florbetaben is currently being evaluated in a phase 3 multicenter trial for the diagnosis of cardiac amyloidosis.
Four Strategies to Address the Tipping Point in Radiology
January 17th 2025In order to flip the script on the impact of the radiology workforce shortage, radiology groups and practices need to make sound investments in technologies and leverage partnerships to mitigate gaps in coverage and maximize workflow efficiencies.
